Treatment.Com International Inc. Closes Non-Brokered Private Placement and Debt Settlement

Vancouver, British Columbia, September 29, 2023 – Treatment.com International Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that further to its news release dated August 18, 2023, the Company has completed the previously announced non-brokered private placement of common shares in the capital of the Company (the “Common Shares”) at a price of $0.10 per Common Share for aggregate gross proceeds of $1,000,000 (the “Offering”) and the previously announced debt settlement of $1,800,000 (the “Debt Settlement”). The Company issued 18,000,000 Common Shares at $0.10 per Common Share to settle $1,800,000 liabilities of the Company. The Company obtained shareholders’ approval with respect to the Offering and the Debt Settlement.

The Offering was completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions. Accordingly, the Common Shares issued in the Offering are not subject to a statutory hold period in accordance with applicable Canadian securities laws. There is an offering document related to the Offering, which can be accessed under the Company’s profile at www.sedarplus.ca and at https://treatment.com/. Prospective investors should read this offering document prior to making any investment decisions.

In connection with the Offering, the Company paid a finder’s fee to an eligible finder (the “Finder”) equal to: (i) a cash commission in the amount of $17,500, being 7.0% of the aggregate gross proceeds raised from investors introduced by the Finder; and (ii) 175,000 non-transferable share purchase warrants (each, a “Finder’s Warrant”), being 7.0% of the aggregate Common Shares purchased by investors introduced by the Finder, in consideration for the Common Shares purchased by investors introduced by the Finder. Each Finder’s Warrant entitles the holder thereof to acquire one (1) Common Share at a price of $0.255 per Common Share until September 29, 2025.

The Company intends on using the net proceeds of the Offering for general working capital purposes.

The securities issued pursuant to the Offering have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities issued pursuant to the Offering may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Release issued by: Kevin Peterson, Interim CEO

Main Line: +1 (612) 788-8900

Toll Free USA/Canada: +1 (888) 788-8955

Cautionary Statement

 This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, the use of proceeds of the Offering, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

Neither the Canadian Securities Exchange nor its regulation services provider have reviewed or accept responsibility for the adequacy or accuracy of this release.